Clinical Trial

Short-course Radiotherapy Combined With Furoquintinib and PD-1 Monoclonal Antibody

Study acronym: PMMR/MSS
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The investigators conduct a single-arm, single-center, prospective clinical study enrolling patients diagnoses with pMMR / MSS type middle and low locally advanced rectal cancer who had not received systemic anti-tumor therapy to explore the efficacy and safety of short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody as neoadjuvant therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-25.
Trial Details
NCT Number NCT06014944
Lead Sponsor Changhai Hospital
Conditions Rectal Cancer
Enrollment 30 participants
Start Date 2023-09-01
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-08-31